Celgene

Manager, Environmental Health and Safety

Posted on: 8 Mar 2021

Devens, MA

Job Description

At Bristol Myers Squibb, we are inspired by a single vision transforming patients lives through science. In oncology, hematology, immunology and cardiovascular disease and one of the most diverse and promising pipelines in the industry each of our passionate colleagues contribute to innovations that drive meaningful change. We bring a human touch to every treatment we pioneer. Join us and make a difference.

* Collaborate with both site and global EHS to develop and implement best in class EHS programs for the site. These programs may include but are not limited to Contractor safety, Biosafety, Industrial Hygiene, General Site Safety, and Waste management.
* Program support includes execution of facility self-assessments to ensure EHS program compliance, and ownership of resulting action plans. Assessments may be completed independently or as part of a team.
* Using a client representation model, support day-to-day activities in one or more operational function across the Devens site. This may include Commercial and/or Clinical drug substance manufacturing, support of maintenance and metrology activities, Warehouse, Laboratories (quality control and process development), and Cell Therapy Manufacturing.
* Client representation requires working closely with representatives from Manufacturing, Quality, Supply Chain, Site Engineering, and process development as a key EHS point of contact. Attend daily, weekly, or monthly governance meetings as needed to support operations.
* Perform necessary work place hazard/risk/exposure/ergonomic assessments for current and future process introductions documented in appropriate change management or new material introduction process. Work with outside consultation as needed to determine risk mitigation.
* Ensure compliance with Hazardous Communication labeling for raw materials and products.
* Collaborate with client to ensure on time completion and documentation of area inspections, and support STOP observation program.
* Supports on time incident classification, investigation closure (through support and approval), and action plan closure for both EHS and client group. Work closely with client representation to ensure on time closure of commitments.
* Support the EHS training program by assisting in the development and delivery of training materials for all site EHS programs, and New Employee orientation.
* Influence the environmental, health and safety compliance programs at the facility through active planning, assessment, and correction of work activities conducted by both BMS and contract employees.
* Primary focus of the role will be occupational safety and health with limited support to environment program elements as needed.

BMSBL, BMSBLDMA

Around the world, we are passionate about making an impact on the lives of patients with serious diseases. Empowered to apply our individual talents and diverse perspectives in an inclusive culture, our shared values of passion, innovation, urgency, accountability, inclusion and integrity bring out the highest potential of each of our colleagues.

Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives.

Our company is committed to ensuring that people with disabilities can excel through a transparent recruitment process, reasonable workplace adjustments and ongoing support in their roles. Applicants can request an approval of accommodation prior to accepting a job offer. If you require reasonable accommodation in completing this application, or any part of the recruitment process direct your inquiries to adastaffingsupport@bms.com. Visit careers.bms.com/eeo-accessibility to access our complete Equal Employment Opportunity statement.

Celgene

Summit, NJ

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

The company’s products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology.

The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; EXSCIENTIA LTD.; and IMIDomics SL, as well as immuno-oncology collaboration with Sutro Biopharma. Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.